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at a Tertiary Care Hospital in Karachi
Z. Samad,A. Rashid,M. A. U. Khan,S. Mithani,M. H. Khan,M. S. M. Khan,S. S. Malik,U. S.
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Abstract
Objective:Acute Myocardial Infarction (AMI) is a rising epidemic in developing
countries. While studies in the West have established the characteristics and management
of AMI patients, comprehensive data reflecting these issues in the Pakistani subjects is
scarce. This study examined the profile and management of AMI in patients hospitalized
at a tertiary care hospital in Karachi, Pakistan.
Methods:Three hundred forty four patients admitted in 1998 with the diagnosis of AMI
met our inclusion criteria. Data on presentation, investigations, monitoring and therapy
was obtained. Chi-square and t tests were used to analyze the data.
Results:Out of 344 patients with AMI, 71% were males; 58% had a Q wave Ml. Majority
of the patients who presented within 2 hours of symptom onset (36%), had chest pain.
Patients with dyspnea and no chest pain were more likely to present after 12 hours of the
onset of symptoms. In-house mortality was found to be 10.8%. Low HDL and diabetes
was associated with in-hospital complications. Twenty nine percent of patients were
given thrombolytic therapy with a mean door-to-needle time of 1 hour 36 minutes; 33%
of patients who were eligible of Streptokinase did not receive it. Cardiac catheterization
was performed in 28% patients. Echocardiography and Exercise Tolerance Test, both
under utilized, were performed in 67% and 16% of patients, respectively. Two hundred
sixteen (70%) patients discharged from hospital were contacted via telephone and the 1year mortality rate among them was 28%.
Conclusion:The profile and management of AMP was in coherence with earlier, Western
studies. Chest pain units need to be established in the Emergency Room. Patients should
be risk stratified prior to discharge. Public awareness regarding primary and secondary
prevention and symptoms of AMI needs to be increased (JPMA 52:45, 2002).
Introduction
Atherosclerotic coronary artery disease (CAD) is among the leading cause of death
throughout the world1,2. In 1990 cardiovascular disease (CVD) claimed 14 million lives,
two thirds of which were in the developing countries3. The prevalence of CAD in
Pakistan is probably as higb as in developed countries4. In developed countries, the acute
myocardial infarction (AM!) in-hospital mortality has registered a decline from 30%
three decades ago, to less than 8% in the 90’s5. This decline in mortality has largely been
attributed to dramatic changes in management strategies over the past few decades6. The
management of AM! initially focused on treatment and/or prevention of complications. In
the pre-thrombolytic era, the therapeutic regimens mainly comprised of the use of antianginal and anti-arrhythmic drugs7. The demonstration that the vast majority of AM! are

caused by an occlusive thrombus in the coronary artery, together with the concept that
myocardium can be salvaged within a period of time after the onset of such occlusion,
herald a new era of management of this disorder8. Data shows that coronary flow can be
re established using intravenous thrombolytics, coronary angioplasty, or coronary arterybypass grafting9-11. Adjuvant therapy for AM! should also include Aspirin12, betablocking agents13, Hepari14 and in most patients, Angiotensin-converting enzyme
inhibitors15. Postinfarction, the use of Aspirin, beta-blockers16, ACEIs17 and lipid
lowering agents18 has shown a survival benefit.
Although widely known, these technologies are not consistently applied19,20.
Recommended treatments are still under utilized in patients with AM!20. Sufficient data
regarding the utilization of therapies and in-hospital AM! mortality for Pakistan is
lacking.
Clinical characteristics and simple bedside laboratory tests can now be used to identify
subsets of patients with AM! at different levels of risks and to adjust treatment
accordingly22. In various studies, risk indicators for death were related to age, gender,
Killip class23, history of smoking24, diabetes, hypertension, previous CAD and a family
history of CAD and hyperlipidemia25. Perhaps as many as a third of all patients are at
very low risk and therefore, can be safely discharged from the hospital within 72 hours26.
The substantial resources thus saved could then be directed towards applying the more
expensive therapies to patients at a higher risk. Although considerable information is
available regarding the prognosis after AMI in western population, little is known about
the fate of Pakistani subjects after AM!. Thus the aim of the study is to see the profile,
management and predictors of mortality in AM! patients presenting to a tertiary care
hospital in Pakistan.
Materials and Methods
This was a retrospective descriptive study of patients with AM! admitted to the
emergency room (ER) of The Aga Khan University Hospital (AKUH) from January 1,
1998 to December31, 1998. Patients with the discharge diagnosis of AM! according to
the ICD-9, were included using a list generated by the coding department of AKUH.
Patients were excluded if there was an obvious coding error, transferred to or from
another hospital (to avoid tertiary referral bias), if the MI developed following Coronary
artery bypass grafting (CABG) or any other invasive procedure, if they developed AM!
while in hospital for another reason.
Data Collection
Data was taken from the clinical history, coded at the time of hospital discharge.
Information was obtained on patient’s signs and symptoms, medical history, cardiac
enzyme levels, hospital course, monitoring and therapy. Diagnosis of AM! in the charts
was based on any two of the following three criterion: (1) Typical chest pain; (2) ST
changes in one standard or two precordial leads and (3) Rise in CK concentration more
than twice the normal. Variables were evaluated to determine their ability to predict
cardiac deaths. In-hospital deaths were classified into categories of cardiac and noncardiac causes after a review of hospital records. Follow up after discharge was obtained
from charts and later telephone. Details of readmission and other procedures (CABG,
angioplasty etc.) were also obtained.

Statistical Analysis
All data was transferred from pre coded data sheets to a computed database for analysis
using SPSS 8.0. P< 0.05 was considered statistically significant. The association between
mortality as the dependant variable and all other variables as independent variables was
evaluated using Chi square. Student’s t test was used to assess differences between
continuous variables. All categorical characteristics are described as percent and
continuous measures are summarized with medians and means.
Results
Among the 344 patients studied retrospectively, 71 percent were male and 29 percent
were female. Age was normally distributed with a range of 25 to 92 years and a mean of
60 years.
Risk factors
The risk factors associated with AM! in our population are shown in Table 1.

Presenting sign, symptoms and time to presentation are shown in Table 2a and 2b.

The median duration of symptoms was four hours and the mode was two hours. The
majority of patients presented before 2 hours (37%) or after twelve hours (36%).
Streptokinase
Streptokinase was given to 29% of patients and median door-to-needle time was 40
minutes. The mean time to Streptokinase administration was 1 hour and 36 minutes (SD
± 4 hours, 26 minutes). One third of those eligible for Streptokinase therapy (neither late
presentation nor contraindications for the treatment) did not receive it. There was no
significant gender bias in the treatment provided.
Investigations and Procedures
Electrocardiogram (EKG) was performed on all patients in the ER. Serial lab
investigations, echocardiogram, and exercise tolerance test were not done on the entire
study population (Table 3).

Hospital procedures include cardiac catheterization in 28 percent, CABG in 9 percent and
PTCA in 6 percent. Cardiac catheterization (OR: 4.4, 95% CI: 1.9-10.2, p
Medications
At the time of admission, medications already in use, included nitrates (27%), aspirin
(24%), beta blockers (22%), ACE! (15%), and calcium channel blockers (CCB)(13%).
Only 5 percent patients were on lipid lowering drugs. In the emergency room, the most
commonly administered medications were as follows: aspirin (65%), intravenous (IV)
heparin (53%), IV nitrates (58%), sublingual nitrates (44%), and oxygen (44%).
Morphine was given to 30 percent while 24 percent required diuretics. It is important to
note that only 22 percent of patients received either IV or oral beta-blockers. During
hospital stay, the majority of patients received aspirin (90%), IV heparin (77%), oral
nitrates (66%), ACEI (62%), or oral beta-blockers (60%). On discharge, patients were
most frequently prescribed aspirin (78%), oral nitrates (62%), oral beta-blockers (6 1%),
and ACE! (48%). Only 28% patients were sent with a In-Hospital Course and Mortality
The median hospital stay was 9 days (S.D. 7.4) with median CCU/CSDU stay of 4 days
(S.D. 5.4). In-hospital complications occurred in 33% of patients. The most common
being CHF requiring diuretics (37%), recurrent angina (34%) and cardiac shock requiring
pressors (29%).
Thirty-seven deaths were recorded which constituted an overall mortality of 10.8 percent.
In-hospital mortality was compared with patient variables. Gender had no significant
association with in-hospital mortality. Age and peripheral vascular disease was associated
with in-hospital mortality. Among the presenting symptoms (Table 4) syncope/cardiac
arrest was a predictor of mortality, while the others had no significant association. EKG
findings on presentation had no relation with mortality (Table 4).

Overall, in-hospital complications were strongly associated with in-hospital mortality
(OR: 18.2, 95% CI: 6.8-48.2,p
The population was divided into those with ST elevation and those with ST depression. A
comparison of all risk factors and in-hospital mortality was done for the individual
subsets. The significant associations are summarized in Tables 5a and 5b.

Investigations were found to predict in-hospital mortality. Survivors had higher LVEF
(j’O.O2), lower peak CKMB values (p=<0.Ol), and lower peak CK values (p<0.01).
Severity of myocardial infarction was studied using the following parameters: CCU stay,
Killip class, in-type of myocardial infarction. compared with risk factors. The with a
longer CCU stay was Risk factors associated with II were: age > 60 (p-O.O4), history of
CAD (p-O.O3), and presentation after 12 hours (p=O.OO9). Age greater than 60 years,
diabetes, and current smoking were associated with ST elevation on electrocardiogram
(p=0.06, p=O.09, p=0.Q4 respectively) whereas, a prior history of CAD was associated
with ST depression (p=0.001). Patients more likely (borderline significance) to have inhospital complications were diabetics (p==O.07), those having low HDL (p=0.O5) and
those having a prior history of in-hospital complications. (p0.OO 1).
Mortality on Follow-up
Three hundred and seven patients were discharged; 216 patients were available for
follow-up. By 6 January, 2000, 28 percent patients had expired. Gender did not influence
mortality. Among the initial presenting symptoms, dyspnea (OR: 0.4, 95% CI: 0.2-0.8, p.
Discussion

When analyzing the age distribution of patients with AMI, the mean age of 60 years
correlated well with the Western demographics27, but disagreed with the past studies in
Pakistan, which reported that Pakistani patients are young, aged 40 and 45, and therefore
affected by premature CAD28. The in-hospital mortality rate was 10.8% and increased
with age greater than 60. This is comparable to that of developed countries, where, inhospital mortality rate in the best centers ranges from 7.4% to 8%7. Most patients
presented with chest pain (76%). Only one-third (37%) of the patients presented in less
than 2 hours, and most of these patients had chest pain. Thus, chest pain is readily
recognized as a symptom of “heart attack” and early hospital care is sought. It has been
shown that the greatest benefit of thrombolytic therapy occurs if treatment is initiated
within the first 1 - 3 hours, when a 50% or greater reduction in mortality can be
achieved12. The magnitude of benefit declines rapidly thereafter. Unfortunately, nearly
one-third (36%) of the patients presented after 12 hours, and most of them had symptoms
of dyspnea (32%), or “ghabrahat” (apprehension), which are not readily recognized as
symptoms of “heart attack”, by the layman. This leads to the late presentation to the
hospital. Hence, the need arises to increase public awareness regarding symptoms
associated with the painless infarction (like dyspnea, diaphoresis, apprehension).
More than half (52%) of the patients’ population had previous coronary artery disease.
About one-fifth of the patients were already taking aspirin, beta-blockers and nitrates
when they presented while a few (13 to 15%) were on CCB and ACE!. The lack of
secondary prevention, which aims at delaying the progression and complication of CAD
after it is manifest, is highlighted by the fact that only 5% of the patients at presentation
were on lipid lowering drugs. Hypertension (HTN) (47%) and diabetes (40%) were major
co-morbids in almost one-half of our patients. Epidemiological studies have already
identified these as important risk factors for coronary heart disease29. In-hospital
complications were more likely in those who had diabetes and low HDL (<35mg/dl). In
the ER, aspirin, IV and sublingual nitrates, IV heparin and oxygen was the mainstay of
treatment. Thrombolytic therapy (streptokinase) was given to 29% of the patients. A
study conducted in the USA in 1993, reported that 35.1% of the AM! patients received
thrombolytic therapy30. In our study, the mean this could be the multi-purpose ER, which
caters to all kinds of patients. This thus calls for the establishment of Chest Pain Units.
(CPU) within the ER where a rigorous assessment of patients presenting with chest pain
can be carried out and they can be rapidly triaged and dealt accordingly. A prospective
randomized trial established that a CPU located in the ER and managed by the ER staff;
can be a safe, effective and cost saving means of assuring that patients with chest pain
receive appropriate care31. We also found that 33% of the patients who were eligible for
streptokinase, (no contraindications, nor late presentation), did not receive it. The reasons
for this remain obscure.
Mean length of stay in CCU was 4 days, comparable to the reported mean of 3.3 in the
United States7. Smokers stayed in the CCU for a longer duration as compared to nonsmokers. Hence, smoking is associated with increased morbidity and cost of healthcare32.
In-hospital mortality was 5.8 times more likely in patients who presented with syncope
and cardiac arrest. This finding agrees with previous studies, as most hypotensive patients
have moderate to severe left ventricular dysfunction and thus a poor prognosis23.
Fifty eight percent of the patients had Q wave Ml, similar to the Western figure of
51.5%7. The magnitude of peak creatinine kinase elevation in serum was higher in those

who died. Similar association has been reported in past studies7. A series of clinical trials
have demonstrated the importance of elevated LDL cholesterol in the pathogenesis of
atherosclerosis and the substantial benefit of treating hyperlipidemia in preventing this
condition18. Only about one-third of the patients (n130) had their lipid profiles
documented in their medical records. This might have been due to late presentation, (>24
hours) when the lipid profiles become unreliable.
Echocardiography provides a convenient bedside assessment of left ventricular, global
and regional function. It has been used successfully to make judgments about admission
and management of patients with suspected infarction23. Despite this, echo was
performed only on 67% patients and wall motion abnormality was seen in 84% of these
cases. The reasons behind this low rate of investigation could be a failure to document the
echo reports, cost issues or technical difficulties.
The goal of preventing reinfarction and death, postMI has led to strategies to evaluate
risk. Early after infarction, this evaluation involves the use of non-invasive testing. In
stable patients, sub-maxmal Exercise Tolerance Test (E1’T) may be carried out prior to
hospital discharge to detect residual ischemia and ventricular ectopy, and to provide the
patient with a guideline for exercise. Stress testing may also help in building the patient’s
confidence towards a reasonable exercise tolerance33. Our study demonstrated an under
utilization of this useful investigation. Only 16% patients underwent a predischarge ETT
with more than half (59%) being positive (ST changes, chest pain). This might have been
due to lack of patient compliance, cost issues, documentation errors, or doubts in the
physician’s mind regarding the efficacy of this tool. The most common in-hospital
procedures were cardiac catheterization and CABG. Both were associated with increased
survival on follow-up. This could be due to timely identification of the culprit artery and
appropriate intervention.
In-hospital use of aspirin, oral beta-blockers, oral nitrates and ACE inhibitors,
significantly decreased in-hospital mortality. This result is compatible with known effects
of aspirin and beta-blockers12,13. On discharge, aspirin, oral nitrates, and oral betablockers were given to a great majority (61 to 78%) of the patients and half the patients
received ACE inhibitor. Despite the proven efficacy of lipid lowering agents in primary
and secondary prevention of CAD18, only about one-fourth of the patients (28%),
received lipid lowering agents on discharge.
Two hundred sixteen (70%) of the patients who were discharged home were contacted
again by telephone, and the 1-year mortality rate among them was 28%. The high
mortality rate could be because of poor follow-up, comorbids, lack of compliance to
treatment, or may reflect the need to re-examine the present management strategies.
Limitions
Small size of the patient population available for our study, in our view, is the main
limitation of our study. It is a retrospective survey, with inability to control the quality of
the data. The exact reason for patient-to-patient variability regarding treatment was not
noted. This is an important factor, which should be considered if any subsequent
management protocol is to be developed in the future on the basis of our study results.
The general epidemiology, risk factor profile, mortality and management of AM! in our
population was in coherence with the studies from the developed countries.
Improvements can be made in triaging patients with chest pain by establishing CPUs. An
organized plan for rehabilitation of Post-MI patients can be made, using predischarge

investigations for risk stratification of these patients. Furthermore, public awareness
programs are needed to increase the awareness regarding primary and secondary
prevention, and the presenting symptoms of CAD. Treatment practices in other hospitals
of Pakistan should also be studied to assess the mortality rate and identify any needs for
improvement in the management strategies.
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